Compare Alcon AG (ALC) vs Gap Inc (GAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Gap Inc — how do they compare? Alcon AG trades at $66.7 (market cap $32.69B), while Gap Inc trades at $18.36 (market cap $6.86B). The key difference: Alcon AG is far larger — about 4.8× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.67%). Which is the better fit depends on your goals.
| ALC | GAP | |
|---|---|---|
Market Cap | $32.69B | $6.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $29.13 |
52-Week Low | $62.02 | $18.68 |
Enterprise Value | $36.28B | $9.95B |
Dividend Yield | 0.54% | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Gap trades at $19.07, down 0.94% on the day, with a bearish technical signal despite oversold RSI readings. The stock shows strong fundamentals with a P/E of 7.69, net income margin of 6.25%, and robust cash flow. Recent news highlights a turnaround in progress, with nine consecutive positive comps and AI-driven marketing initiatives, though legal investigations and Athleta's rebuild create headwinds.
The outlook is mixed: valuation metrics suggest undervaluation with a consensus price target of $27, but technical weakness and legal risks temper near-term optimism. Earnings growth and digital transformation are key catalysts, while investor sentiment remains cautious amid ongoing legal scrutiny and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
